Robert Winn, MD, of Virginia Commonwealth University discusses EGFR, KRAS, and ALK, three of the main biomarkers for non-small-cell lung cancers, and the importance of testing for these to deliver precision medicine. He also encourages patients to ask which additional biomarkers will be included in the test panel.
Share with family and friends:
Click here to take our SURVEY Your feedback is important to us! We will use your feedback to develop future areas of content about lung cancer which will help other patients, caregivers and families.
This educational activity has been developed by
A Breath of Hope Lung Foundation and Mechanisms in Medicine Inc.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Foundation Inc., Bristol-Myers Squibb Grants and Giving, Celgene Corporation, Foundation Medicine, Genentech, Novartis, and Pfizer.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.